Adjunctive treatment of adrenocortical carcinoma

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 3, 2008, Pages 221-226

  Terzolo, Massimo ^a,c   Berruti, Alfredo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Adjunctive treatment; Adrenocortical cancer; Mitotane; Radiotherapy

Indexed keywords

CHLORPHENOTANE; CORTICOTROPIN; CORTISONE; DRUG BINDING PROTEIN; ELECTROLYTE; GLUCOCORTICOID; HYDROCORTISONE; MITOTANE; THYROXINE;

ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; METABOLIC CLEARANCE RATE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PRACTICE GUIDELINE; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SURGERY; TREATMENT OUTCOME;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; MITOTANE; NEOPLASM RECURRENCE, LOCAL;

EID: 42649092876     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282fdf4c0     Document Type: Review

References (38)

1. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88:711-736.
2. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001; 25:914-926.
3. Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 60:273-287. A comprehensive review providing an excellent update on the clinical management of ACC.
4. Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997; 122:1212-1218.
5. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25:891-897.
6. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6:719-726.
7. Pommier RF, Brennan MF. An 11-year experience with adrenocortical carcinoma. Surgery 1992; 112:963-970.
8. Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982; 117:1142-1146.
9. Venkatesh S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. Cancer 1989; 64:765-769.
10. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20:941-950.
11. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006; 91:2650-2655. A retrospective study on the largest series of patients with ACC from a single institution.
12. Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989; 141:257-260.
13. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995; 75:2587-2591.
14. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195-2001.
15. Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2000; 33:1191-1196.
16. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o,p′-DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92:1385-1392.
17. Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998; 83:3100-3103.
18. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71:3119-3123.
19. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69:947-951.
20. Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997; 54:490-496.
21. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992; 112:972-979.
22. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p′-DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000; 11:1281-1287.
23. Fassnacht M, Hahner S, Buelent Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:4501-4504. A case-control, retrospective study on adjuvant radiotherapy following radical resection of ACC.
24. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12:667-680.
25. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372-2380. A retrospective, multicenter study on a large series of patients with ACC showing that adjuvant mitotane prolongs disease-free survival in treated patients compared with two independent and contemporary groups of untreated patients.
26. Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma [letter to the editor]. N Engl J Med 2007; 357:1256-1259.
27. ••] providing an interesting contribute to the debate on adjuvant mitotane treatment.
28. Machens A, Dralle H. Adjuvant mitotane in adrenocortical carcinoma [letter to the editor]. N Engl J Med 2007; 357:1258-1259.
29. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85:2234-2238.
30. Terzolo M, Fassnacht M, Berruti A. Adjuvant mitotane in adrenocortical carcinoma [letter to the editor]. N Engl J Med 2007; 357:1259.
31. Lee JE. Adjuvant mitotane in adrenocortical carcinoma [letter to the editor]. N Engl J Med 2007; 357:1256-1258.
32. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res 2000; 33:1197-1200.
33. Libé R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14:13-28. A comprehensive review focusing particularly on pathophysiology of ACC.
34. Dickstein G, Shechner C, Natif O. Adjuvant mitotane in adrenocortical carcinoma. letter to the editor. N Engl J Med 2007; 357:1256-1257.
35. Faggiano A, Leboulleux S, Young J, et al. Rapidly progressing high o,p′-DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol 2006; 64:110-113. A study reporting feasibility of a high-dose regimen of mitotane.
36. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p′-DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol 1989; 31:51-57.
37. Daffara FC, De Francia S, Reimondo G. et al. Biochemical effects of adjuvant mitotane treatment in patients with adrenocortical cancer: results of 1-year follow-up. Proceedings of the 89th Annual Meeting of the Endocrine Society; OR29-5, Toronto, June 2-5 2007.
38. Nancy Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 2006; 91:2165-2170. A study demonstrating an oestrogen-like effect of mitotane.